BMS's Phase III RELATIVITY-098 Trial of Opdualag Fails to Meet Primary Endpoint in Adjuvant Melanoma Treatment
Bristol-Myers Squibb
Biopharmaceutical and Nutritional Product R&D and Sales
On February 13, BMS announced that Opdualag (a fixed-dose combination of nivolumab and relatlimab) is used for adjuvant treatment in patients with completely resected stage III-IV melanoma.Phase III RELATIVITY-098 Study，Failed to reach the primary endpoint of recurrence-free survival (RFS)。
In this analysis, the safety of Opdualag was observed to be consistent with the known safety profiles of nivolumab and relatlimab.
Source: BMS Official Website
RELATIVITY-098 is a randomized, double-blind Phase III clinical study designed to evaluate the efficacy and safety of Opdualag as adjuvant therapy versus nivolumab monotherapy in patients with completely resected Stage III-IV melanoma. The primary endpoint is RFS, with secondary endpoints including overall survival (OS), distant metastasis-free survival (DMFS), and safety.
Opdualag isFirst-in-class dual immunotherapy fixed-dose combination, containing the PD1 inhibitor nivolumab and the LAG3 inhibitor relatlimab. In March 2022, this product was approved by the U.S. FDA for the treatment of adult and pediatric patients aged 12 years and older with unresectable or metastatic melanoma.
Dr. Jeffrey Walch, Vice President and Global Program Lead of Opdualag at Bristol-Myers Squibb, stated: "We are disappointed with the results of the RELATIVITY-098 study, as LAG3 inhibition in the adjuvant setting did not deliver the same efficacy improvement seen in advanced melanoma. Patients who have had their tumors completely removed prior to treatment may not have sufficient anti-tumor T-cells for Opdualag to reach its full potential. However, Opdualag remains the standard of care for first-line treatment of unresectable or metastatic melanoma, and we will continue to explore its potential across various tumor types, including non-small cell lung cancer."
Cover Source:Corporate Logo
Disclaimer:This article is for information sharing only,不代表 Insight 立场和观点, and does not recommend or introduce any treatment options. If needed, please consult and contact正规医疗机构.
Editor: Crescent
PR Article Coordination: WeChat insightxb
SubmissionWeChat: insightxb; Email: insight@dxy.cn
Diversified functions, traceable data……
Insight Database Web Version Awaits Your Experience
Click to read the original text,ImmediatelyUnlock！
